Loek Eggermont obtained his
master's degree in Molecular Life Sciences at the Radboud
University Nijmegen in 2013. During his master's, he performed
internships concerning bioorthogonal chemistry, chemical biology
and biochemistry. In August 2013, he joined the Department of Tumor
Immunology as a PhD student to work on the development of synthetic
dendritic cells for improved cancer immunotherapies.